HK1091205A1 - Isethionate salt of a selective cdk4 inhibitor - Google Patents

Isethionate salt of a selective cdk4 inhibitor

Info

Publication number
HK1091205A1
HK1091205A1 HK06111868.0A HK06111868A HK1091205A1 HK 1091205 A1 HK1091205 A1 HK 1091205A1 HK 06111868 A HK06111868 A HK 06111868A HK 1091205 A1 HK1091205 A1 HK 1091205A1
Authority
HK
Hong Kong
Prior art keywords
cdk4 inhibitor
selective cdk4
isethionate salt
isethionate
salt
Prior art date
Application number
HK06111868.0A
Other languages
English (en)
Inventor
Vladimir Genukh Beylin
Anthony Clyde Blackburn
David Thomas Erdman
Peter Laurence Toogood
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of HK1091205A1 publication Critical patent/HK1091205A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HK06111868.0A 2003-07-11 2006-10-27 Isethionate salt of a selective cdk4 inhibitor HK1091205A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48635103P 2003-07-11 2003-07-11
PCT/IB2004/002152 WO2005005426A1 (en) 2003-07-11 2004-06-28 Isethionate salt of a selective cdk4 inhibitor

Publications (1)

Publication Number Publication Date
HK1091205A1 true HK1091205A1 (en) 2007-01-12

Family

ID=34062121

Family Applications (1)

Application Number Title Priority Date Filing Date
HK06111868.0A HK1091205A1 (en) 2003-07-11 2006-10-27 Isethionate salt of a selective cdk4 inhibitor

Country Status (32)

Country Link
US (2) US7345171B2 (zh)
EP (1) EP1648889B1 (zh)
JP (1) JP4053073B2 (zh)
KR (1) KR100816945B1 (zh)
CN (1) CN1835951B (zh)
AR (1) AR045898A1 (zh)
AT (1) ATE412650T1 (zh)
AU (1) AU2004255934B2 (zh)
BR (1) BRPI0412516A (zh)
CA (1) CA2532049C (zh)
CL (1) CL2004001701A1 (zh)
CY (1) CY1108589T1 (zh)
DE (1) DE602004017474D1 (zh)
DK (1) DK1648889T3 (zh)
ES (1) ES2313016T3 (zh)
GT (1) GT200400130A (zh)
HK (1) HK1091205A1 (zh)
IL (1) IL173034A (zh)
MX (1) MXPA06000484A (zh)
NL (1) NL1026624C2 (zh)
NO (1) NO335100B1 (zh)
NZ (1) NZ544609A (zh)
PA (1) PA8606501A1 (zh)
PE (1) PE20050700A1 (zh)
PL (1) PL1648889T3 (zh)
PT (1) PT1648889E (zh)
RU (1) RU2317296C2 (zh)
SI (1) SI1648889T1 (zh)
TW (1) TWI288750B (zh)
UY (1) UY28404A1 (zh)
WO (1) WO2005005426A1 (zh)
ZA (1) ZA200600230B (zh)

Families Citing this family (123)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP1767A (en) 2002-01-22 2007-08-13 Warner Lambert Co 2-(pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones.
EP1740184A1 (en) * 2004-03-30 2007-01-10 Pfizer Products Incorporated Combinations of signal transduction inhibitors
EP1931670B1 (en) * 2005-10-07 2012-09-12 Exelixis, Inc. Pyridopyrimidinone inhibitors of pi3k
KR20140105621A (ko) * 2005-10-07 2014-09-01 엑셀리시스, 인코포레이티드 ＰＩ３Ｋα의 피리도피리미디논 억제제
CN101511829A (zh) 2006-09-08 2009-08-19 辉瑞产品公司 2-（吡啶-2-基氨基）-吡啶并[2,3-d]嘧啶-7-酮的合成
EP2074122B9 (en) 2006-09-15 2013-09-11 Pfizer Products Inc. Pyrido (2, 3-d) pyrimidin0ne compounds and their use as pi3 inhibitors
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
WO2008076946A2 (en) * 2006-12-14 2008-06-26 Panacea Pharmaceuticals, Inc. Methods of neuroprotection by cyclin-dependent kinase inhibition
WO2009061345A2 (en) * 2007-11-07 2009-05-14 Cornell Research Foundation, Inc. Targeting cdk4 and cdk6 in cancer therapy
JP5537439B2 (ja) * 2007-12-19 2014-07-02 アムジエン・インコーポレーテツド 細胞周期阻害剤としての縮合ピリジン、ピリミジンおよびトリアジン化合物
EP2278973B1 (en) * 2008-04-07 2011-11-02 Amgen Inc. Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors
CN102231984A (zh) * 2008-10-01 2011-11-02 北卡罗来纳大学查珀尔希尔分校 使用选择性细胞周期蛋白依赖性激酶4/6抑制剂对抗化疗化合物的造血防护
CN102231983A (zh) * 2008-10-01 2011-11-02 北卡罗来纳大学查珀尔希尔分校 使用选择性细胞周期蛋白依赖性激酶4/6抑制剂对抗电离辐射的造血防护
JO2885B1 (en) * 2008-12-22 2015-03-15 ايلي ليلي اند كومباني Protein kinase inhibitors
SG173178A1 (en) 2009-04-03 2011-09-29 Hoffmann La Roche Propane- i-sulfonic acid {3- [5- (4 -chloro-phenyl) -1h-pyrrolo [2, 3-b] pyridine-3-carbonyl] -2, 4-difluoro-pheny l } -amide compositions and uses thereof
JP2012526850A (ja) 2009-05-13 2012-11-01 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル サイクリン依存性キナーゼ阻害剤及びその用法
JP2013510166A (ja) 2009-11-06 2013-03-21 プレキシコン インコーポレーテッド キナーゼ調節のための化合物、方法およびその適用
NZ601033A (en) 2009-12-31 2014-02-28 Ct Nac Investigaciones Oncologicas Cnio Tricyclic compounds for use as kinase inhibitors
TWI510487B (zh) 2010-04-21 2015-12-01 Plexxikon Inc 用於激酶調節的化合物和方法及其適應症
US8691830B2 (en) 2010-10-25 2014-04-08 G1 Therapeutics, Inc. CDK inhibitors
JP2013545758A (ja) * 2010-11-17 2013-12-26 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル 増殖性キナーゼｃｄｋ４及びｃｄｋ６の阻害による虚血からの腎組織の保護
WO2012098387A1 (en) 2011-01-18 2012-07-26 Centro Nacional De Investigaciones Oncológicas (Cnio) 6, 7-ring-fused triazolo [4, 3 - b] pyridazine derivatives as pim inhibitors
RS58455B1 (sr) 2011-02-07 2019-04-30 Plexxikon Inc Jedinjenja i postupci za modulaciju kinaze, i indikacije za njih
ES2620521T3 (es) 2011-03-23 2017-06-28 Amgen Inc. Inhibidores duales tricíclicos condensados de CDK 4/6 y FLT3
WO2012173694A1 (en) 2011-06-17 2012-12-20 Fluidic, Inc. Ionic liquid containing sulfonate ions
CA2868966C (en) 2012-03-29 2021-01-26 Francis Xavier Tavares Lactam kinase inhibitors
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
SI2958916T1 (sl) 2013-02-21 2018-11-30 Pfizer Inc. Trdne oblike selektivnih zaviralcev CDK4/6
JP6337083B2 (ja) 2013-03-15 2018-06-06 ジー１、セラピューティクス、インコーポレイテッドＧ１ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Ｒｂポジティブ異常細胞増殖に対するｈｓｐｃ温存治療
CA2904054A1 (en) * 2013-03-15 2014-09-25 Concert Pharmaceuticals, Inc. Deuterated palbociclib
CN107417691B (zh) 2013-03-15 2020-06-26 G1治疗公司 高效的抗赘生剂和抗增生剂
WO2014203129A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Combinations of benzopyran compounds, compositions and uses thereof
WO2015161287A1 (en) 2014-04-17 2015-10-22 G1 Therapeutics, Inc. Tricyclic lactams for use in the protection of normal cells during chemotherapy
CN105294681B (zh) * 2014-07-26 2017-07-07 广东东阳光药业有限公司 Cdk类小分子抑制剂的化合物及其用途
WO2016016769A1 (en) * 2014-07-31 2016-02-04 Sun Pharmaceutical Industries Limited A process for the preparation of palbociclib
WO2016024249A1 (en) * 2014-08-14 2016-02-18 Sun Pharmaceutical Industries Limited Crystalline forms of palbociclib
WO2016040848A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
EP3191098A4 (en) 2014-09-12 2018-04-25 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
CN105622638B (zh) * 2014-10-29 2018-10-02 广州必贝特医药技术有限公司 嘧啶或吡啶并吡啶酮类化合物及其制备方法和应用
WO2016066420A1 (en) * 2014-10-29 2016-05-06 Sandoz Ag Crystalline forms of palbociclib monohydrochloride
CN105616419A (zh) * 2014-11-07 2016-06-01 江苏豪森药业集团有限公司 含有细胞周期蛋白抑制剂固体分散体的药物组合物及其制备方法
CN105616418A (zh) * 2014-11-07 2016-06-01 江苏豪森药业集团有限公司 含有细胞周期蛋白抑制剂的药物制剂及其制备方法
CA2967595A1 (en) 2014-11-12 2016-05-19 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
WO2016090257A1 (en) * 2014-12-05 2016-06-09 Crystal Pharmatech Inc. Salts and crystalline forms of 6-acetyl-8-cyclopentyl-5-methyl-2((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d] pyrimidin-7(8h)-one (palbociclib)
WO2016092442A1 (en) * 2014-12-08 2016-06-16 Sun Pharmaceutical Industries Limited Processes for the preparation of crystalline forms of palbociclib acetate
CN105732615B (zh) * 2014-12-31 2018-05-01 山东轩竹医药科技有限公司 Cdk激酶抑制剂
AU2016214897B9 (en) * 2015-02-03 2020-06-04 Jiangsu Hengrui Medicine Co., Ltd. Hydroxyethyl sulfonate of cyclin-dependent protein kinase inhibitor, crystalline form thereof and preparation method therefor
CZ201589A3 (cs) 2015-02-11 2016-08-24 Zentiva, K.S. Pevné formy soli Palbociclibu
AR104068A1 (es) 2015-03-26 2017-06-21 Hoffmann La Roche Combinaciones de un compuesto inhibidor de fosfoinosítido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cáncer
EP3078663A1 (en) 2015-04-09 2016-10-12 Sandoz Ag Modified particles of palbociclib
WO2016156070A1 (en) 2015-04-02 2016-10-06 Sandoz Ag Modified particles of palbociclib
CN104910149A (zh) * 2015-04-28 2015-09-16 上海百奇医药科技有限公司 一种Palbociclib制备方法
CN106117199A (zh) * 2015-05-04 2016-11-16 江苏恒瑞医药股份有限公司 一种细胞周期蛋白依赖性激酶抑制剂的二羟乙基磺酸盐、其结晶形式及其制备方法
LT3305785T (lt) * 2015-05-29 2021-11-10 Teijin Pharma Limited Pirido[3,4-d]pirimidino dariniai ir jų farmaciniu požiūriu priimtinos druskos
KR102068423B1 (ko) 2015-06-04 2020-01-20 화이자 인코포레이티드 팔보시클립의 고체 투여 형태
CN106317053A (zh) * 2015-06-29 2017-01-11 北大方正集团有限公司 一种帕博昔布晶型a的制备方法
SI3331881T1 (sl) 2015-08-05 2019-08-30 Ratiopharm Gmbh Nova kristalna oblika in adukti palbocikliba in matanojske kisline
CN105085517B (zh) * 2015-08-06 2016-11-23 天津华洛康生物科技有限公司 一种结晶型帕博西尼游离碱水合物及其制备方法
CN106474129A (zh) * 2015-09-01 2017-03-08 上海方楠生物科技有限公司 一种帕博西林或其药学上可接受的盐与药用辅料的组合物及其制备方法
HU230962B1 (hu) * 2015-10-28 2019-06-28 Egis Gyógyszergyár Zrt. Palbociclib sók
IL302822A (en) 2015-11-12 2023-07-01 Seagen Inc Compounds interacting with glycans and methods of use
CN105418603A (zh) * 2015-11-17 2016-03-23 重庆莱美药业股份有限公司 一种高纯度帕布昔利布及其反应中间体的制备方法
CN106800554A (zh) * 2015-11-26 2017-06-06 上海科胜药物研发有限公司 一种帕博西尼二盐酸盐的晶型及其制备方法
CN106800553A (zh) * 2015-11-26 2017-06-06 上海科胜药物研发有限公司 一种帕博西尼二羟乙基磺酸盐的晶型
CN105541832A (zh) * 2015-12-15 2016-05-04 南京艾德凯腾生物医药有限责任公司 一种羟乙基磺酸盐帕布昔利布的制备方法
WO2017130219A1 (en) 2016-01-25 2017-08-03 Mylan Laboratories Limited Amorphous solid dispersion of palbociclib
WO2017145054A1 (en) 2016-02-24 2017-08-31 Lupin Limited Modified particles of crystalline palbociclib free base and process for the preparation thereof
CN107137408A (zh) * 2016-03-01 2017-09-08 江苏恒瑞医药股份有限公司 一种cdk4/6抑制剂与芳香化酶抑制剂联合在制备治疗乳腺癌的药物中的用途
CN107137409A (zh) * 2016-03-01 2017-09-08 江苏恒瑞医药股份有限公司 一种cdk4/6抑制剂与雌激素受体拮抗剂联合在制备治疗乳腺癌的药物中的用途
US10690673B2 (en) 2016-03-29 2020-06-23 Mayo Foundation For Medical Education And Research Method of treating cancer metastasis by CDK 4/6 inhibitors
US10449195B2 (en) 2016-03-29 2019-10-22 Shenzhen Pharmacin Co., Ltd. Pharmaceutical formulation of palbociclib and a preparation method thereof
WO2018001270A1 (en) * 2016-06-30 2018-01-04 Noratech Pharmaceuticals, Inc. Palbociclib prodrugs and composition thereof
WO2018005863A1 (en) 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Pyrimidine-based compounds for the treatment of cancer
WO2018009735A1 (en) 2016-07-07 2018-01-11 Plantex Ltd. Solid state forms of palbociclib dimesylate
SI3497103T1 (sl) 2016-08-15 2021-07-30 Pfizer Inc. Zaviralci piridopirimdiona CDK2/4/6
US10710999B2 (en) 2016-10-07 2020-07-14 Mylan Laboratories Limited Polymorph of an intermediate for palbociclib synthesis
WO2018073574A1 (en) 2016-10-20 2018-04-26 Cipla Limited Polymorphic forms of palbociclib
EP3804724B1 (en) 2016-10-20 2022-12-07 Pfizer Inc. Cdk inhibitors for treating pah
US20190275049A1 (en) 2016-11-16 2019-09-12 Pfizer Inc. Combination of an EGFR T790M Inhibitor and a CDK Inhibitor for the Treatment of Non-Small Cell Lung Cancer
EP3541847A4 (en) 2016-11-17 2020-07-08 Seattle Genetics, Inc. COMPOUNDS INTERACTING WITH GLYCANE AND METHODS OF USE
TWI755452B (zh) * 2016-11-28 2022-02-21 日商帝人製藥股份有限公司 吡啶并〔３﹐４-ｄ〕嘧啶衍生物或其溶劑合物之結晶
JP7229162B2 (ja) 2017-01-06 2023-02-27 ジー１ セラピューティクス， インコーポレイテッド 癌の治療に対する併用療法
KR102653141B1 (ko) 2017-03-03 2024-04-01 씨젠 인크. 글리칸-상호작용 화합물 및 사용 방법
WO2018191950A1 (en) * 2017-04-21 2018-10-25 Alnova Pharmaceuticals, Ltd. Palbociclib compositions and methods thereof
FI3645001T3 (fi) 2017-06-29 2024-09-25 G1 Therapeutics Inc Git38:n morfisia muotoja ja niiden valmistusmenetelmiä
EA202090402A1 (ru) 2017-07-28 2020-05-19 Синтон Б.В. Фармацевтическая композиция, содержащая пальбоциклиб
KR20200115583A (ko) 2018-01-29 2020-10-07 베타 파마, 인크. Cdk4 및 cdk6 억제제로서의 2h-인다졸 유도체 및 그의 치료 용도
CN112041307B (zh) 2018-02-06 2024-02-09 伊利诺伊大学评议会 作为选择性雌激素受体降解剂的取代的苯并噻吩类似物
CA3092003A1 (en) 2018-02-27 2019-09-06 Pfizer Inc. Combination of a cyclin dependent kinase inhibitor and a bet-bromodomain inhibitor
PL3793609T3 (pl) 2018-05-14 2024-05-13 Pfizer Inc. Preparat w postaci doustnego roztworu
CA3106273A1 (en) 2018-07-23 2020-01-30 F. Hoffmann-La Roche Ag Methods of treating cancer with pi3k inhibitor, gdc-0077
WO2020041770A1 (en) 2018-08-24 2020-02-27 G1 Therapeutics, Inc. Improved synthesis of 1,4-diazaspiro[5.5]undecan-3-one
JP6952747B2 (ja) 2018-09-18 2021-10-20 ファイザー・インク がん処置のためのＴＧＦβ阻害剤およびＣＤＫ阻害剤の組合せ
EP3863618A1 (en) 2018-10-08 2021-08-18 F. Hoffmann-La Roche AG Methods of treating cancer with pi3k alpha inhibitors and metformin
US11424484B2 (en) 2019-01-24 2022-08-23 Octet Scientific, Inc. Zinc battery electrolyte additive
US20220125777A1 (en) 2019-02-01 2022-04-28 Pfizer Inc. Combination of a cdk inhibitor and a pim inhibitor
WO2020239558A1 (en) 2019-05-24 2020-12-03 Pfizer Inc. Combination therapies using cdk inhibitors
WO2020240360A1 (en) 2019-05-24 2020-12-03 Pfizer Inc. Combination therapies using cdk inhibitors
CN112094272A (zh) 2019-06-18 2020-12-18 北京睿熙生物科技有限公司 Cdk激酶抑制剂
CN110143948B (zh) * 2019-06-21 2021-05-14 上海博悦生物科技有限公司 Cdk4/6抑制剂、其药物组合物、制备方法及应用
KR20220108085A (ko) 2019-12-03 2022-08-02 제넨테크, 인크. 유방암 치료를 위한 병용 요법
US20230117684A1 (en) 2020-03-05 2023-04-20 Pfizer Inc. Combination of an anaplastic lymphoma kinase inhibitor and a cyclin dependent kinase inhibitor
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof
WO2022013369A1 (en) 2020-07-15 2022-01-20 Pfizer Inc. Kat6 inhibitor methods and combinations for cancer treatment
WO2022018596A1 (en) 2020-07-20 2022-01-27 Pfizer Inc. Combination therapy
WO2022063119A1 (zh) * 2020-09-24 2022-03-31 南京济群医药科技股份有限公司 一种羟乙磺酸哌柏西利的组合物及药物
CN114306245A (zh) 2020-09-29 2022-04-12 深圳市药欣生物科技有限公司 无定形固体分散体的药物组合物及其制备方法
WO2022091001A1 (en) 2020-10-29 2022-05-05 Pfizer Ireland Pharmaceuticals Process for preparation of palbociclib
WO2022123419A1 (en) 2020-12-08 2022-06-16 Pfizer Inc. Treatment of luminal subtypes of hr-positive, her2-negative early breast cancer with palbociclib
CN113845520A (zh) * 2021-09-09 2021-12-28 安徽皓元药业有限公司 一种帕布昔利布乳清酸盐及其制备方法
KR20240118134A (ko) 2021-12-10 2024-08-02 일라이 릴리 앤드 캄파니 Cdk4 및 6 억제제로 이전에 치료된 환자에서의 호르몬 수용체-양성, 인간 표피 성장 인자 수용체 2-음성 진행성 또는 전이성 유방암의 치료를 위한 풀베스트란트와 조합된 cdk4 및 6 억제제
WO2023111810A1 (en) 2021-12-14 2023-06-22 Pfizer Inc. Combination therapies and uses for treating cancer
WO2023114264A1 (en) 2021-12-15 2023-06-22 Eli Lilly And Company Combination for treatment of high-risk metastatic hormone-sensitive prostate cancer
CN114195784A (zh) * 2021-12-29 2022-03-18 斯坦德标准技术研究(湖北)有限公司 帕博西尼有关物质及其制备方法和应用
EP4302832A1 (en) 2022-07-07 2024-01-10 Lotus Pharmaceutical Co., Ltd. Palbociclib formulation containing glucono delta lactone
EP4302755A1 (en) 2022-07-07 2024-01-10 Lotus Pharmaceutical Co., Ltd. Palbociclib formulation containing an amino acid
WO2024023703A1 (en) 2022-07-29 2024-02-01 Pfizer Inc. Dosing regimens comprising a kat6 inhibitor for the treatment of cancer
TW202416991A (zh) 2022-08-31 2024-05-01 美商亞文納營運公司 雌激素受體降解劑之給藥方案
WO2024097206A1 (en) 2022-11-02 2024-05-10 Petra Pharma Corporation Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of disease
WO2024132652A1 (en) 2022-12-22 2024-06-27 Synthon B.V. Pharmaceutical composition comprising palbociclib
WO2024133726A1 (en) 2022-12-22 2024-06-27 Synthon B.V. Pharmaceutical composition comprising palbociclib
WO2024201334A1 (en) 2023-03-30 2024-10-03 Pfizer Inc. Kat6a as a predictive biomarker for treatment with a kat6a inhibitor and methods of treatment thereof
WO2024201340A1 (en) 2023-03-30 2024-10-03 Pfizer Inc. Kat6a as a predictive biomarker for treatment of breast cancer with a cdk4 inhibitor and an antiestrogen and methods of treatment thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6720332B2 (en) * 2000-09-01 2004-04-13 Smithkline Beecham Corporation Oxindole derivatives
JP2005524609A (ja) * 2001-12-17 2005-08-18 スミスクライン ビーチャム コーポレーション ピラゾロピリダジン誘導体
AP1767A (en) * 2002-01-22 2007-08-13 Warner Lambert Co 2-(pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones.
WO2004032882A2 (en) * 2002-10-10 2004-04-22 Smithkline Beecham Corporation Chemical compounds
EA008865B1 (ru) * 2002-11-22 2007-08-31 Смитклайн Бичам Корпорейшн Производные 2-имино-4-оксотиазолидина
WO2004065378A1 (en) * 2003-01-17 2004-08-05 Warner-Lambert Company Llc 2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation
WO2004076414A2 (en) * 2003-02-27 2004-09-10 Smithkline Beecham Corporation Novel compounds

Also Published As

Publication number Publication date
DE602004017474D1 (de) 2008-12-11
CN1835951B (zh) 2010-06-02
US7863278B2 (en) 2011-01-04
PL1648889T3 (pl) 2009-03-31
US7345171B2 (en) 2008-03-18
KR20060054300A (ko) 2006-05-22
NL1026624A1 (nl) 2005-01-12
MXPA06000484A (es) 2006-04-05
UY28404A1 (es) 2005-02-28
GT200400130A (es) 2005-07-14
CN1835951A (zh) 2006-09-20
SI1648889T1 (sl) 2009-02-28
NL1026624C2 (nl) 2005-07-20
PT1648889E (pt) 2008-12-10
ZA200600230B (en) 2007-04-25
PA8606501A1 (es) 2005-03-03
US20050059670A1 (en) 2005-03-17
JP2007530425A (ja) 2007-11-01
CA2532049C (en) 2010-07-20
NO20060386L (no) 2006-04-05
US20080021037A1 (en) 2008-01-24
AU2004255934A1 (en) 2005-01-20
TW200516079A (en) 2005-05-16
RU2006101052A (ru) 2006-07-27
CL2004001701A1 (es) 2005-06-03
TWI288750B (en) 2007-10-21
ATE412650T1 (de) 2008-11-15
EP1648889B1 (en) 2008-10-29
IL173034A (en) 2010-06-16
AR045898A1 (es) 2005-11-16
RU2317296C2 (ru) 2008-02-20
AU2004255934B2 (en) 2010-02-25
BRPI0412516A (pt) 2006-09-19
EP1648889A1 (en) 2006-04-26
ES2313016T3 (es) 2009-03-01
CA2532049A1 (en) 2005-01-20
WO2005005426A1 (en) 2005-01-20
PE20050700A1 (es) 2005-10-18
DK1648889T3 (da) 2009-01-05
KR100816945B1 (ko) 2008-03-25
CY1108589T1 (el) 2014-04-09
IL173034A0 (en) 2006-06-11
NO335100B1 (no) 2014-09-15
NZ544609A (en) 2008-07-31
JP4053073B2 (ja) 2008-02-27

Similar Documents

Publication Publication Date Title
HK1091205A1 (en) Isethionate salt of a selective cdk4 inhibitor
HK1139681A1 (en) Salts of valsartan
HK1080069A1 (zh) 環氧酶2-抑制劑的硝酰氧基衍生物
GB2403489B (en) Expandable tubulars
AP2109A (en) Combinations of a pyrimidine containing NNRTI withRT inhibitors
HK1077762A1 (zh) TFGß[轉化生長因子]的抑制劑
IL174592A0 (en) Processes for the preparation of a polymorph of fluvastantin sodium
ZA200501418B (en) Benzenesulfonate salts of 4-fluoro-2-cyanopyrrolidine derivatives
SI1501804T1 (sl) Derivati izokinolina kot MAO-B inhibitorji
PL373523A1 (en) Indol-2-ones as selective inhibitors of cyclooxygenase-2
GB0311195D0 (en) Glyoxalase inhibitors
EP1549616A4 (en) SALT OF AMLODIPIN WITH AN ORGANIC SOURCE
GB2428721B (en) Expandable tubulars
GB0220125D0 (en) Method of forming pocketted sponges
GB0318913D0 (en) Apoptosis inhibitors
AU2003902208A0 (en) Inhibitor of cox
AU2003258982A8 (en) Methods of inhibiting pin1-associated states using a fredericamycin a compound
GB2430952B (en) Methods of forming a centraliser
GB0309120D0 (en) A set of parts
AU157275S (en) A set of bowls
GB0326554D0 (en) Serfer of a wall
GB0311194D0 (en) Glyoxalase i inhibitors
SE0302451D0 (sv) a new salt
GB0325222D0 (en) Corrosion inhibitor
AU154873S (en) A set of bowls

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20240627